Tag

Zoloft Archives - Carey Danis & Lowe

New Study: Celexa & Zoloft Disrupt Unborn Baby Bone Growth

By | Pharmaceutical litigation, Uncategorized, Zoloft

topamax_birth_defects_topamax_lawsuit_settlementsCelexa and Zoloft, two drugs used to treat depression, are linked to many types of birth defects. And according to a recently published study, these two antidepressants are now linked to poor bone development.

The study, Citalopram and sertraline exposure compromises embryonic bone development, appeared in Molecular Psychiatry in September 2015.

The researchers looked at bone development in zebrafish embryos and human adult stem cells.

In both cases, they discovered that exposure to either Celexa (citalopram) or Zoloft (sertraline) resulted in inhibited bone growth.

In concluding their findings, the researchers emphasized that, “[t]hese results highlight the need to further investigate the risks of SSRI use during pregnancy in exposing unborn babies to potential skeletal abnormalities.”

WE CAN HELP YOU

Do you have questions about use of antidepressants like Celexa and Zoloft during pregnancy?

If so, contact the law offices of Carey Danis & Lowe. Our team includes experienced trial attorneys and medical professionals, who are both available to answer your questions and discuss your concerns.

If you used a selective serotonin reuptake inhibitor (SSRI) antidepressant, such as Celexa or Zoloft, during your pregnancy, and your child was born with birth defects, we encourage you to contact one of our SSRI birth defect lawyers today.

We offer free case evaluations, and can help you decide whether filing a Celexa or Zoloft birth defect lawsuit is right for you and your family.

Contact Carey Danis & Lowe today.

You can reach us by phone at 800.721.2519, or by completing a confidential personal injury claim form.

 

 

New Study Links Prozac & Paxil with Birth Defects

By | Paxil, Pharmaceutical litigation, Prozac, Uncategorized

ssri_birth_defectsA study published in the British Medical Journal links certain antidepressants with birth defects when used by pregnant women. The National Center on Birth Defects and Developmental Disabilities in Atlanta led the study.

Researchers looked at selective serotonin reuptake inhibitors, a class of antidepressants often referred to as SSRIs. The SSRIs included in the study were Paxil, Prozac, Celexa, Lexapro, and Zoloft.

The researchers recorded an increase in birth defects in children whose mothers used Prozac or Paxil early in their pregnancy. They reviewed 28,000 pregnancies between 1997 and 2009.

When women used Paxil one month before or during their first trimester, the risk of birth defects increased. For anencephaly, or a deformation of the skull, the risk rose from 2 per 10,000 to 7 per 10,000. For heart defects, the risk rose from 10 per 10,000 to 24 per 10,000.

In their study, the researchers emphasized that the Prozac and Paxil birth defects risk is small, but their findings do show a link. In light of this link, they called for further studies into the use of SSRI antidepressants in pregnant women.

It is highly recommended to speak with an obstetrician and mental health professional in order to make an informed decision about using SSRI antidepressants during pregnancy.

You are not alone.

At Carey Danis & Lowe, we understand the pain and suffering caused by birth defects. That’s why our team of experienced attorneys works tirelessly to recover losses for families impacted by Prozac birth defects or Paxil birth defects.

Interested in exploring your legal options?

Contact Carey Danis & Lowe today. We offer free case evaluations, during which we discuss your case, your compensation eligibility, and whether filing a Prozac or Paxil birth defects lawsuit is right for you.

You can reach our St. Louis law firm by phone at 800.721.2519, or by completing a confidential personal injury claim form.

We look forward to hearing from you, and offering you any assistance that we can.

First Zoloft Birth Defects Lawsuit to Go to Trial: What Pfizer Knew

By | Pharmaceutical litigation, Uncategorized, Zoloft

Zoloft MDL Updates: Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect CasesPfizer knew about the link between Zoloft use during pregnancy and birth defects in newborn babies. However, they decided to ignore this crucial patient safety information. A lawyer in the first Zoloft birth defects lawsuit to go to trial shared this with the jury during closing arguments in a state court in St. Louis on April 17, 2015.

The lawyer pointed specifically to an internal document dating before 1991 that included the recommendation that women able to become pregnant shouldn’t use Zoloft due to birth defect risks.

Furthermore, the lawyer argued that, even with knowledge of Zoloft and birth defects risks, Pfizer made no move to issue a sufficient warning. Pfizer didn’t update Zoloft’s drug safety label; therefore, doctors and patients were left in the dark about the dangers of Zoloft use during pregnancy.

The lawyer represents the plaintiffs in the case, the Pesante family, whose son was born with heart defects after his mother consumed Zoloft during pregnancy.

The son’s heart defects required three open-heart surgeries. Only a month after being born, the boy received a pacemaker.

In a Bloomberg article about the Zoloft trial, the defendants argued in their closing statement that Pfizer did issue warnings, and that these warnings were approved by the U.S. Food and Drug Administration (FDA).

Now, it is up to the jury to decide if Pfizer did indeed issue a sufficient warning, or if the company should be held liable for the harm done to the Pesante family and their son.

We can help your family

Carey Danis & Lowe is a St. Louis law firm that currently represents families whose children have been harmed by Zoloft in the womb. Our defective drug lawyers work tirelessly to recover losses for our clients.

If you would like to discuss your case with us, we are available by phone at 800.721.2519; you can also reach us by completing a confidential personal injury claim form.

We offer free case evaluations, and can help you decide if filing a Zoloft lawsuit is the right decision for you and your family.

 

 

Zoloft Birth Defects Lawsuit Update: Latest Developments in Pennsylvania Zoloft MDL

By | Antidepressant, Pharmaceutical litigation, Uncategorized, Zoloft

SSRI Antidpressant Zoloft Birth Defects LitigationThe latest development to come out of the Zoloft birth defects multidistrict litigation (MDL) in the U.S. District Court for the Eastern District of Pennsylvania involves a back and forth between the plaintiffs and the federal judge handling the MDL. Their discussion involves discovery pool and trial pool case selections.

U.S. District Judge Cynthia M. Rufe is presiding over the Zoloft MDL. In late August, she submitted a trial pool selection guideline. In early September, the plaintiffs filed an objection of Judge Rufe’s selection guidelines, taking issue with the defendants’ ability to remove cases from the discovery pool.

The plaintiffs requested that Judge Rufe update her protocol so that the defendants are unable to remove, or strike, cases from the discovery pool submitted by the same plaintiffs’ legal counsel. The plaintiffs made this request on the basis of maintaining a variety of cases in the initial discovery pool, especially as it pertains to the plaintiffs’ legal counsel.

In the court document about this matter, Judge Rufe stated that the selection process for the discovery and trial pools should not involve reference to the plaintiffs’ legal counsel, as this does not necessarily provide a representative case.

The goal in selecting cases for the discovery and trial pools is to find a representative case suitable for a bellwether trial that supports an efficient legal process, and will aid in post-trial settlement.

Ultimately, Judge Rufe came to the conclusion that the defendants cannot remove two cases from the discovery pool whose plaintiffs are represented by the same legal counsel.

Carey Danis & Lowe Zoloft birth defects lawyers are keeping a watchful eye on the Zoloft MDL as it inches closer and closer to the bellwether trial process. Above all, the multidistrict litigation process makes for an efficient legal process. In regards to the most recent court filing in the Zoloft birth defects MDL, Carey Danis & Lowe hopes that the latest ruling is in keeping with this core purpose.

Carey Danis & Lowe is currently accepting Zoloft birth defects cases. Contact Carey Danis & Lowe today for a free legal consultation about your case, and to determine if you and your family are be eligible for compensation. Our Zoloft attorneys can also assist in filing Zoloft birth defects lawsuits.

If you have questions about Zoloft birth defects, voice your questions and concerns to one of our on-staff nurses.

Share your Zoloft birth defects story with Carey Danis & Lowe by calling 800.721.2519, or by submitting a personal injury claim form.

Zoloft Birth Defects Lawsuit Review

By | Pharmaceutical litigation, Uncategorized, Zoloft

SSRI Antidpressant Zoloft Birth Defects LitigationA court document filed in July in the Zoloft multidistrict litigation (MDL) collected the latest information on Zoloft birth defects lawsuits pending across the U.S. According to the court document, in addition to the consolidated cases in the Pennsylvania Zoloft MDL, there are pending lawsuits in California, Illinois, Missouri, New York, and West Virginia.

In state courts across California, plaintiffs filed a total of 7 lawsuits in July 2013. There three cases pending in Illinois courts, with one lawsuit in St. Clair county involving eight families, and a 38 family case in the Southern District of Illinois.

In Missouri, there are three Zoloft lawsuits pending in courts, and in New York, there are five lawsuits pending in Oneida County and New York County. There is one case pending in the Circuit Court of Wayne County in West Virginia.

As of July 16, 2013, there are over 400 Zoloft lawsuits pending in the Zoloft MDL.

The Zoloft MDL is being heard in the U.S. District Court for the Eastern District of Pennsylvania, and is being overseen by U.S. District Judge Cynthia M. Rufe. The Zoloft MDL is In re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation, MDL No. 2342. The first bellwether case is scheduled to come to trial in October 2014.

Women and their families have filed Zoloft birth defects lawsuits claiming that the use of Zoloft during pregnancy led to congenital birth defects. The most commonly reported birth defects are congenital heart defects, Omphalocele, Craniosynostosis, and persistent pulmonary hypertension of the newborn (PPHN). Visit the Zoloft birth defects information page for a complete Zoloft birth defects list.

Carey Danis & Lowe Zoloft birth defects lawyers work diligently to win justice for those who have been injured by negligent pharmaceutical companies. Our team of legal and medical experts are here to help. If you took Zoloft while pregnant, and your child was born with birth defects, depend upon Carey Danis & Lowe to win you justice and resolution to your troubles and suffering.

Contact Carey Danis & Lowe for a free legal evaluation and for medical advice by calling 800.721.2519, or by submitting a personal injury claim form.

Zoloft Lawsuit News: Injured Parties Continue to File Zoloft Birth Defects Lawsuits

By | Pharmaceutical litigation, Uncategorized, Zoloft

zoloft_heart_birth_defect_ssri_pregnancyAs a national law firm representing individuals in Zoloft birth defects lawsuits, Carey Danis & Lowe has closely been watching for news and updates in Zoloft lawsuits. Earlier this month, a plaintiff filed a Zoloft birth defects lawsuit in St. Clair County Circuit Court in Illinois claiming that her child was born with congenital heart defects. The plaintiff filed her Zoloft lawsuit citing that the maker of Zoloft, Pfizer, did not provide adequate warning about the risks associated with Zoloft use during pregnancy.

In response to the lawsuit, a Pfizer spokesperson was quoted in the Madison-St. Clair Record as saying that the pharmaceutical company intends to defend itself against the charges.

 Zoloft Birth Defects Background

In a study published in 2007 in the New England Journal of Medicine, researchers concluded that taking Zoloft (sertraline) during the first trimester of pregnancy led to two times the risk of the baby being born with a heart defect, especially a hole in the heart. In addition, the study found that the risk of a baby developing omphalocele was 5.7 times higher when exposed to Zoloft in the womb.

An atrial septal defect, also called a hole in the heart, is marked by an atypical hole between the heart’s two upper chambers. In newborn babies who develop a ventricular septal defect, a hole exists between between the heart’s two lower chambers. Omphalocele is a birth defect in which the newborn baby’s abdominal organs protrude from the belly button.

Carey Danis & Lowe Zoloft birth defects lawyers are currently taking Zoloft birth defects cases. For a free legal evaluation of your case and for assistance with filing a Zoloft birth defects lawsuit, contact Carey Danis & Lowe by calling 800.721.2519 or by submitting a personal injury claim form.

Carey Danis & Lowe Evaluating Zoloft Cases and Offers an Update on Zoloft Lawsuits in Zoloft MDL No. 2342

By | Pharmaceutical litigation, Uncategorized, Zoloft

Published January 14, 2013 by PR Web

St. Louis, Missouri (PRWEB) January 14, 2013

Zoloft MDL Updates: Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect CasesZoloft lawsuits have been consolidated into a Multi-District Litigation in the U.S. District Court for the Eastern District of Pennsylvania. Judge Cynthia M. Rufe is presiding over the Zoloft MDL.

As to recent developments in the Zoloft MDL, on January 2, 2013, Judge Rufe sent forth Pretrial Order No. 16. Fundamentally, the Pretrial Order outlines how to deliver responses in the MDL. The court document imparts detailed information as to “the procedure for filing responses to all civil actions that are or become consolidated in MDL No. 2342”.*

The Pretrial Order goes on to supply information on how the defendants, Pfizer Inc., Greenstone LLC, and Pfizer International LLC, shall go about filing a Master Short-Form Answer. In essence, the Master-Short Form Answer and Affirmative Defense is the defendants’ response to the claims of the plaintiffs.

According to the Pretrial Order, the Defendants will only have the opportunity to file one Master Short-Form Answer, and in doing so can address any and all charges made against them in each of the cases consolidated in the Zoloft MDL. As the document will stand as their initial response to allegations, Pfizer and Greenstone can deny the plaintiffs’ allegations, and in so doing, they can lay out a defense.

If relying upon information supplied in a recent report, there are quite a number of Zoloft cases in the MDL, and therefore each of these cases will necessitate address in the defense’s response. A Florida attorney who sits on the Plaintiffs’ Steering Committee (PSC), Bryan F. Aylstock, recently submitted a report late last year regarding the status of the Zoloft MDL. The legal journal, The Madison-St. Clair Record, stated that according to information contained in Alystock’s report, there are over 250 cases that have been consolidated into the Zoloft MDL.*

Plaintiffs in the Zoloft MDL have filed lawsuits against Pfizer, the manufacturer of Zoloft, claiming that the antidepressant drug, classified as a selective serotonin re-uptake inhibitor (SSRI), causes birth defects in newborn children when taken by women during pregnancy.

In a separate Zoloft lawsuit being heard in the Wayne County Circuit Court in West Virginia, nineteen plaintiffs, who are the children of mothers who claimed to have taken Zoloft during pregnancy, filed their lawsuit alleging that exposure to Zoloft in the womb resulted in the development of their birth defects.

According to the legal journal, The West Virginia Record, the plaintiffs identified these Zoloft linked birth defects as heart defects, such as atrial septal defects and holes in the heart, persistent pulmonary hypertension of the newborn (PPHN), skull and facial deformations, and a number of other congenital birth defects related to Zoloft exposure in utero.*

Lawyers at Carey Danis & Lowe are currently evaluating Zoloft cases, and they are offering legal consultations to those individuals who claim to have been harmed by the use of Zoloft during pregnancy. For more information about filing a Zoloft lawsuit, and specifically one related to Zoloft and birth defects, contact a lawyer at Carey Danis & Lowe by calling 800-721-2519.

Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect Cases

By | Pharmaceutical litigation, Uncategorized, Zoloft

Zoloft MDL Updates: Zoloft MDL No. 2342 Progresses with Order to Submit Initial Discovery Zoloft Birth Defect CasesThe Zoloft Multi-District Litigation No. 2342 being heard in the U.S. District Court for the Eastern District of Pennsylvania has made progress as regards setting the date for the first trial. According to Pre-trial Court Order 15, the first trial is currently scheduled for September 12, 2014. This is a tentative date that is dependent upon completion of all pertinent discovery by both sides.

This same court document from the Zoloft MDL details that by January 11, 2013, both the Defense and the Plaintiff’s counsel must deliver selections pertaining to Initial Discovery Group Cases, which will help in determining which cases enter the Trial Pool Cases.

The court has ordered that selections of cases that are representative enough for Trial Pool Cases should be supplied to the court by March 15, 2013.

According to a December 2012 article published by The Madison Record, there are currently 250 Zoloft cases that have been consolidated into the Pennsylvania MDL. What is more, there remain a number of Zoloft lawsuits pending in state courts that have not yet been consolidated into the MDL. State courts hearing these Zoloft lawsuits include Illinois, Missouri, New York, Pennsylvania, and West Virginia.

Plaintiffs in the Zoloft MDL claim that the use of Zoloft during pregnancy resulted in the development of birth defects in newborn children. These Zoloft birth defects include, but are not limited to, the following:

  • Congenital heart defects
  • Atrial septal defects
  • Ventricular septal defects
  • Omphalocele
  • Craniosynostosis
  • Persistent Pulmonary Hypertension of the Newborn (PPHN)

Zoloft is an anti-depressant drug manufactured by Pfizer. Zoloft is categorized as a selective serotonin re-uptake inhibitor, or SSRI. These types of antidepressants have a strong link to the development of birth defects in children exposed to an SSRI drug while in the womb.

If your newborn child was exposed to the SSRI medication Zoloft while in the womb, and as a result, developed life-altering and health compromising birth defects, you and your child may be entitled to receive recompense for your physical suffering, emotional suffering, and medical expenses.

For more information about filing a Zoloft birth defect lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe. Our pharmaceutical product liability lawyers will provide you with a free legal consultation about your Zoloft case. Call a Zoloft lawyer at Carey Danis & Lowe today at 800.721.2519.

The Injurious Link Between SSRI Antidepressants and Birth Defects

By | Antidepressant, Pharmaceutical litigation, Uncategorized

Published September 13, 2012 on Carey & Danis

The Injurious Link Between SSRI Antidepressants and Birth DefectsA grave conundrum is presented to women who suffer from depression during pregnancy. There are significant mental and physical health issues that must be considered in regards to medicating with a selective serotonin re-uptake inhibitor (SSRI) antidepressant such as Celexa, Lexapro, Luvox, Symbyax, Paxil, Zoloft, or Prozac while pregnant. Ending use of an SSRI antidepressant during pregnancy poses a risk to the mother’s mental health as well as to the unborn child, depending on when discontinuance of the medication occurs.

If an SSRI antidepressant was taken by the pregnant mother into the third trimester, it has been discovered that these antidepressant medications leach through the placental sack, thus exposing the unborn child to the drugs, often causing a chemical attachment resulting in withdrawal upon the child’s birth or the mother’s sudden termination of SSRI use.Signs of withdrawal in the newborn child are irritable mood, breathing complications, trembling, feeding problems, and hypoglycemia.

In recognition of these withdrawal symptoms in newborn children, the U.S. Food and Drug Administration (FDA) in 2004 released a warning in regards to the use of SSRI antidepressants by pregnant women in their third trimester. In their statement, the FDA made the recommendation that pregnant women medicating with an SSRI antidepressant be placed on a schedule which over time would gradually lower their dosage of an antidepressant.

Though this FDA warning and recommendation was targeted at the prevention of withdrawal symptoms in the newborn child, such near termination of SSRI antidepressant use by the pregnant mother was seen to cause serious mental health issues including a severe episode of postpartum depression. Drug withdrawal is not the only source of suffering inflicted on an unborn child exposed to SSRI antidepressants.

Epidemiology magazine examined in their May 2012 issue a recent study on the health of pregnant mothers using SSRI antidepressants. The study found that there is a significant link between the use of an SSRI antidepressant and pre-term delivery. In this specific study led by the Yale School of Public Health, the SSRI under examination was Paxil. Use of Paxil and other SSRI antidepressants while pregnant have also been linked to a number of other birth defects that cause an undue amount of suffering for a newborn child. These SSRI-linked birth defects include Persistent Pulmonary Hypertension of the Newborn (PPHN), omphalocele, craniosynostosis, atrial septal defects, and ventricular septal defects.

If an SSRI antidepressant was used during pregnancy and a newborn child suffered from a birth defect, compensation for such unfair suffering is due. Contact a knowledgeable pharmaceutical product liability litigation attorney at Carey Danis & Lowe for more information about filing a lawsuit against the manufacturers of Celexa, Lexapro, Luvox, Symbyax, Paxil, Zoloft, or Prozac.

Zoloft Multi-district Litigation Status Conference Scheduled In Pennsylvania

By | Pharmaceutical litigation, Uncategorized, Zoloft

Published May 29, 2012 by LawsuitInformation.org

Zoloft Multi-district Litigation Status Conference In PennsylvaniaFederal lawsuits dealing with birth defects stemming from the popular antidepressant Zoloft were consolidated in a multidistrict litigation case in the Eastern District of Pennsylvania on the 17th of April, 2012. The first status conference, according to an order issued on the 4th of May by presiding District Judge Cynthia M. Rowley, is scheduled for the 12th of July, 2012.

These lawsuits all have several things in common, including the defendant—Pfizer, the drug making giant responsible for the popular antidepressant Zoloft, which is an SSRI drug used in the treatment of general anxiety disorder, post traumatic stress disorder, and other relatively common psychological conditions. The lawsuits also all deal with Zoloft birth defects.

Birth defects common Zoloft lawsuit complaint

Thousands of parents have filed lawsuits across the country after mothers have given birth to children with serious birth defects as a result of their Zoloft use during pregnancy. In many cases, the mothers say they were led to believe that the drug was safe to use, and that they would never have taken it had they known of the risk of potential serious side effects associated with the medications. Their lawyers often claim that the drug makers didn’t adequately conduct clinical trials on the medication before releasing it to the pharmaceuticals market, nor did they adequately warn patients about the risk of these side effects.

The multidistrict litigation case was consolidated in order to streamline pretrial processes dealing with these lawsuits, which will help them be completed more quickly, getting plaintiffs settlements faster. When pretrial processes are completed, many of the lawsuits will be remanded, or sent back to the courts from which they came. At the initial meeting that was recently scheduled, it is likely that each party involved in the litigation will suggest procedures that will lead to the resolution of the litigation and help it move quickly and fairly.

Damages sought in Zoloft lawsuits

Plaintiffs who have filed a Zoloft lawsuit have a lot in common, including a desire for compensation that could cover the costs of their or their child’s past and future medical care. Inclusion in the federal multidistrict litigation case could really help to expedite the legal process for a number of plaintiffs. Studies backing up the claim that Zoloft use by pregnant women could cause birth defects are being cited in these lawsuits, and the combination of several Zoloft cases could help to strengthen the suits even more.